Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Grants totalling almost £350,000 will be made to three Oxford University scientists for their research to combat a devastating muscle-wasting condition, a national charity has announced today.

Source: Muscular Dystrophy Campaign press release

Professor Dame Kay Davies, Professor Matthew Wood and Dr Angela Russell will receive the grants for their research projects to improve understanding of or explore potential treatments for Duchenne muscular dystrophy. The grants have been awarded by charity the Muscular Dystrophy Campaign and fellow members of the Duchenne Forum, and will be awarded over a two or four-year period.

One hundred children are born in the UK each year with Duchenne muscular dystrophy. The condition, which almost always affects boys, is caused by the lack of a vital muscle protein and causes muscles to weaken and waste over time, leading to increasing and severe disability. It affects not only the muscles of the limbs, but also those of the heart and lungs, and few of those born with the condition will live to see their 30th birthday.

Professor Dame Kay Davies’ project will build on her previous work attempting to increase levels of a muscle protein which may compensate for that which is lacking in people affected by Duchenne muscular dystrophy. One drug developed for this purpose by Professor Davies and her colleagues is already in clinical trial. Dr Russell’s work will complement Professor Davies’ work and will seek to better understand how this potential treatment could work. Professor Wood will identify ‘biomarkers’, biological indicators that can be used to measure the progression of Duchenne muscular dystrophy, and a patient’s response to future treatments during clinical trials.

The grants are among seven being awarded by the Duchenne Forum, a collaboration established between six charities to accelerate progress in the search for effective treatments and cures for Duchenne muscular dystrophy. The Duchenne Forum charities are the Muscular Dystrophy Campaign, Alex’s Wish, Duchenne Children’s Trust, Duchenne Research Fund, Joining Jack and Harrison’s Fund.

Dr Marita Pohlschmidt, Director of Research for the Muscular Dystrophy Campaign, said: “Following the dedicated fundraising efforts of our supporters, we are delighted to be able to back the vital work of these three highly respected scientists. Duchenne muscular dystrophy is a devastating condition and we will continue to fund a comprehensive programme of research until treatments are found for every single person affected.”

Professor Dame Kay Davies said:  “This grant makes a big difference to us as it allows the continued screening of the cell line we developed with previous funding from the Muscular Dystrophy Campaign. This approach, which is being carried out in collaboration with Dr Angela Russell in the Chemistry department of Oxford University, will allow us to identify novel hits which increase utrophin levels which we can develop as drug leads.”

Professor Matthew Wood said: "We are very grateful that the Muscular Dystrophy Campaign has decided to support this PhD project which looks at the levels of microRNAs for Duchenne muscular dystrophy. These microRNAs are short pieces of RNA which may be detected in blood. Certain microRNAs change following treatment so we want to use them as biomarkers as it provides an easy and non-invasive way of looking at how well a treatment is working. We are hoping to expand on this and find even better biomarkers."

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.

Oxford-led technology to help those at high risk from Covid-19

Coronavirus COVID-19 General Research

More people in England at high risk from Covid-19 will get priority access to vaccines thanks to new technology developed by a University of Oxford-led team of researchers that can identify those who may be most vulnerable to the virus.